Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28202312 | 0.98 | EGFR (0.50) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL4593258 | 0.93 | EGFR (0.51) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 | |
| Hydrochloric Acid SCHEMBL27988358 | 0.92 | EGFR (0.50) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 | |
| Formaldehyde SCHEMBL28199969 | 0.87 | EGFR (0.46) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL6030966 | 0.85 | EGFR (0.46) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL241727 | 0.85 | EGFR (0.58) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 | |
| Hydrochloric Acid SCHEMBL8814048 | 0.84 | EGFR (0.56) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL28703821 | 0.82 | EGFR (0.44) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL3896815 | 0.81 | EGFR (0.53) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 | |
| Formaldehyde SCHEMBL28061098 | 0.81 | EGFR (0.53) | EGFRFGFR4PDGFRBPDGFRAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113200966-B | Furosetinib derivative, pharmaceutical composition and application | 深圳大学 | 2022-07-22 | — | — | CN | disclosed |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008020302-A2 | HETEROAROMATIC QUINOLINE-BASED COMPOUNDS AS PHOSPHODIESTERASE (PDE) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020302-A2 | HETEROAROMATIC QUINOLINE-BASED COMPOUNDS AS PHOSPHODIESTERASE (PDE) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | BRAF, RAF1, NRAS | EGFR 1237/4885FGFR4 1512/4885PDGFRB 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.